Hls Therapeutics Inc (HLS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 5,508 | 5,856 | 5,919 | 7,047 | 8,207 |
| Income taxes - deferred | -47 | 3,861 | -61 | 107 | -541 |
| Accounts receivable | -1,241 | 346 | 837 | 221 | 1,154 |
| Accounts payable and accrued liabilities | 851 | -969 | -519 | -380 | 1,471 |
| Other Working Capital | 2 | 843 | 301 | 1,087 | 2,392 |
| Other Operating Activity | -3,572 | -7,418 | -5,699 | -4,348 | -7,316 |
| Operating Cash Flow | $1,501 | $2,519 | $778 | $3,734 | $5,367 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | 0 | -2 | -14 | 0 |
| Purchase Sale Intangibles | 0 | N/A | N/A | 0 | -40 |
| Other Investing Activity | -1,500 | 13,250 | 0 | 0 | 0 |
| Investing Cash Flow | $-1,500 | $13,250 | $-2 | $-14 | $-40 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -15,096 | -1,605 | -2,218 | -3,306 | -2,328 |
| Common Stock Repurchased | 0 | -317 | -283 | -580 | -603 |
| Other Financing Activity | 0 | -658 | -533 | 0 | -1,360 |
| Financing Cash Flow | $-15,096 | $-2,580 | $-3,034 | $-3,886 | $-4,291 |
| Exchange Rate Effect | 120 | -117 | -251 | 310 | -160 |
| Beginning Cash Position | 32,515 | 19,443 | 21,952 | 21,808 | 20,932 |
| End Cash Position | 17,540 | 32,515 | 19,443 | 21,952 | 21,808 |
| Net Cash Flow | $-15,095 | $13,189 | $-2,258 | $-166 | $1,036 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,501 | 2,519 | 778 | 3,734 | 5,367 |
| Capital Expenditure | N/A | N/A | -2 | -14 | -40 |
| Free Cash Flow | 1,501 | 2,519 | 776 | 3,720 | 5,327 |